In today’s ACT Brief, we examine how capturing friction in real time can reveal site burden, how OpenAI and Mistral compare on clinical trial matching, and how Boehringer Ingelheim is licensing early-stage oncology programs from SBP Group.
|Webcasts|May 7, 2020
End of Study Hacks: The New Digital Age
Learn from industry experts how to eliminate compliance risks associated with the up to 65% of sites that lose, never receive, or acknowledge these CDs/DVDs, along with the site audits where findings arise due to data access. Live: Thursday, May 7, 2020 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST On demand available after airing until May 7, 2021.
Register free:
Event Overview:
It’s no secret that the end of a study requires immense efforts by sponsors and CROs. One of the regulatory-required and resource-intensive end-of-study steps is sharing the end-of-study media back with the clinical research sites - a compliance process that has relied on dated and unsecure technology, such as CDs and DVDs, and manual efforts. Learn from industry experts how to eliminate compliance risks associated with the up to 65% of sites that lose, never receive, or acknowledge these CDs/DVDs, along with the site audits where findings arise due to data access. Improve site satisfaction and enhance process efficiency by simplifying and automating the exchange of study data with sites. Discover how Sponsors and CROs are challenging the status quo by developing new models to improve end of study compliance and productivity.
Key Learning Objectives:
During this session you will gain an understanding of:
- Current challenges and practices for managing end of study media
- Methods to mitigate security, inspection finding, regulatory risks
- Innovative technologies and practices to challenge the status quo
- Case studies resulting in increased site satisfaction due to new digital content delivery practices
Speakers: Perry Steinberg, VP Product, Medidata, a Dassault Systèmes company
Tim Akers, Solution Specialist, Medidata, a Dassault Systèmes company
Arzu Akturan, Sr. Solution Consultant, Medidata, a Dassault Systèmes company
Time and date: Thursday, May 7, 2020 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST
On demand available after airing until May 7, 2021.
Sponsor: Medidata, a Dassault Systèmes company
Register free:
Related to this article
Mistral and OpenAI produced identical overall eligibility labels across 200 synthetic patient-study assessments, with criterion-level disagreements concentrated in inclusion criteria where models switch between “Uncertain” and “Not included” when records lack sufficient evidence, so model choice should be driven by deployment architecture, control, and cost rather than assumed interchangeability.
In Episode 4 of The Human Side of Clinical Trials, host Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., speaks with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about how capturing friction closer to the moment it happens can reveal unclear instructions, technology friction, and workarounds that retrospective surveys and debriefs tend to miss.
ACT Brief: Community Research Financing Gaps, Neuroscience Endpoint Data, and Teva’s Biosimilar Deal
In today’s ACT Brief, we examine why community research needs lasting financing and infrastructure, how electronic outcome tools can strengthen neuroscience endpoints, and how Teva is licensing two biosimilars from Samsung Bioepis.
Neuroscience trials struggle to show benefit because symptoms are subjective and variable, and eCOA strengthens dossiers by standardizing ClinRO administration, capturing outcomes in real time to reduce recall bias, and adding patient and caregiver perspectives that clinician scales miss.
Community participation gaps look less like a question of patient willingness and more like a financing and infrastructure problem that no single bill has yet solved.
In today’s ACT Brief, we examine what changes when AI is embedded across clinical operations, why faster trial data isn’t yet producing faster decisions, and how FDA granted accelerated approval to a therapy for a rare airway disease.
Data capture is no longer the bottleneck, and whether the lag between a signal and a decision shrinks depends on signal design, AI governance, and vendor orchestration.
Trending on Applied Clinical Trials Online
1
Comparing OpenAI and Mistral on Clinical Trial Matching
2
Embedding AI Across the Clinical Operating Model: Q&A with Rajneesh Patil, Syneos Health
3
From Complexity to Endpoint Meaningfulness: Addressing Key Neuroscience Trial Challenges with eCOA
4
From Signal to Action: Why Faster Trial Data Isn’t Producing Faster Decisions
5